The US is a logical step in our global expansion, say Haselmeier officials, the United States is the largest healthcare market and home to many leading pharmaceutical and biotech companies.
"With the increasing interest in self-injection technology in the US, it is important that we have a facility located in the US," said Frédéric Gabriel, General Manager for Haselmeier GmbH. “The US is only one part in our global expansion”, Gabriel added “and Haselmeier views its presence in the US as a key component of its global strategy.” In addition, Haselmeier, Inc. will seek potential relationships with organizations developing new technology and emerging opportunities in drug delivery.
The US Company will be headed by Robert J. Kilgore, who was previously Vice President of Global Marketing & Business Development for Haselmeier GmbH and has over 25 years of experience with injection technology. Haselmeier Inc. will market Haselmeier’s products and services to the pharmaceutical and biotech industry.
"Our goal is to provide the best possible support and service to customers and increase awareness of Haselmeier’s current and future self-injection platforms." said Robert Kilgore. "We want to be available and responsive to companies evaluating our technology.”